Kevin Ali bought $300K of Organon & (OGN)
Executed May 5 2025, disclosed May 6 2025, 1 day later.
Over the 21 trading sessions from the disclosed entry session (May 6 2025), the stock returned +10.9% (delay-adjusted); from the execution session (May 5 2025), +1.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Kevin Ali (Chief Executive Officer) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Organon & Co. (OGN). Across 1 priced purchase filing, the average 21-session return was +1.1% from execution and +10.9% from disclosure (delay-adjusted; derived). The largest single filing was $300K of OGN (34,000 sh × $8.81, as filed), executed May 5 2025.
Healthcare · Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe,…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→